7Baggers
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

Intensity Therapeutics
(NASDAQ:INTS) 

INTS stock logo

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. Its lead product candidate includes INT230-6, a clinical trial for the treatment of refractory solid tumors and pancreatic, colon,...

Founded: 2012
Sector: TECHNOLOGY
Industry: GENERAL
Healthcare
Share this website to your friends
Intensity Therapeutics Days Payable Outstanding ttm (DPO)
202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 01,081.172,162.333,243.54,324.665,405.836,4877,568.16
Intensity Therapeutics Days Inventory Outstanding ttm (DIO)
202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 0267.47534.94802.411,069.891,337.361,604.831,872.3
Intensity Therapeutics Op Cashflow Per Share ttm
202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -0.7-0.6-0.5-0.4-0.3-0.2-0.10
Intensity Therapeutics Free Cashflow Per Share ttm
202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -0.7-0.6-0.5-0.4-0.3-0.2-0.10
Intensity Therapeutics Cash Per Share ttm
202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 00.160.330.490.650.820.981.15
Intensity Therapeutics (GAAP) P/E ratio ttm
202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -26.73-22.91-19.09-15.27-11.45-7.64-3.820
Intensity Therapeutics P/B ratio ttm
202307 202308 202309 202310 202311 202312 202401 202402 202403 202404 -9.11-6.88-4.64-2.41-0.172.064.36.53
No extra charts and metrics for this ticker.